Unjoni Ewropea - Malti - EMA (European Medicines Agency)

pfizer europe ma eeig - inotuzumab ozogamicin - leukimija limfoblastika taċ-Ċelluli prekursuri-linfoma - aġenti antineoplastiċi - besponsa huwa indikat bħala monoterapija għall-kura ta ' adulti b'all rikadut jew refrattarju cd22-pożittivi taċ-ċellula b prekursur li għandhom lewkimja limfoblastika akuta (all). pazjenti adulti bi prekursur taċ-ċelluli b tal-kromożomi posittivi (ph +) li rkadew jew refrattarji ta 'philadelphia kollha kellhom ikunu fallew il-kura b'inqas minn 1 tyrosine kinase inhibitor (tki).

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

pfizer europe ma eeig - gemtuzumab ozogamicin - lewkimja, mijelojda, akuta - aġenti antineoplastiċi - mylotarg huwa indikat għal terapija kkombinata b'daunorubicin (dnr) u cytarabine (arac) għall-kura ta ' pazjenti età 15-il sena u aktar li ma ġietx ikkurata qabel, de novo cd33 pożittivi għall-lewkimja majelojde akuta (aml), ħlief-lewkimja promijeloċitika akuta (apl).

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

wyeth europa ltd - gemtuzumab ozogamicin - lewkimja, mijelojda, akuta - aġenti antineoplastiċi - mill-ġdid tal-kura ta 'induzzjoni ta cd33-pożittivi aml f'pazjenti adulti fl-ewwel rikaduta li mhumiex kandidati għall-oħra intensiv mill-ġdid l-induzzjoni ta' kimoterapija (e. doża għolja ara-c) u tissodisfax mill-inqas wieħed mill-kriterji li ġejjin: t-tul ta'l-ewwel remissjoni 60 sena.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - elotuzumab - majloma multipla - aġenti antineoplastiċi - empliciti huwa indikat, flimkien ma 'lenalidomide u dexamethasone għall-kura ta' majeloma multipla f'pazjenti adulti li jkunu rċevew mill-anqas terapija waħda qabel (ara sezzjonijiet 4. 2 u 5.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

roche registration gmbh  - pertuzumab - neoplażmi tas-sider - antineoplastic agents, monoclonal antibodies - kanċer metastatiku tas-sider:perjeta huwa indikat għall-użu flimkien ma ' trastuzumab u docetaxel f'pazjenti adulti b'her2 pożittiv metastatiku jew lokalment rikorrenti li ma jistax jitneħħa-kanċer tas-sider, li għadhom ma rċevew l-preċedenti kontra l-her2 it-terapija jew kimoterapija għall-mard metastatiku. miżjuda fil-bidu tat-trattament tal-kanċer tas-sider:perjeta huwa indikat għall-użu flimkien ma 'trastuzumab u l-kemjoterapija għall-miżjuda fil-bidu tat-trattament ta' pazjenti adulti b'her2 pożittiv, lokalment avvanzat, infjammazzjoni, jew kmieni fl-istadju tal-kanċer tas-sider f'riskju għoli ta ' rikorrenza.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

roche registration gmbh - pertuzumab, trastuzumab - neoplażmi tas-sider - aġenti antineoplastiċi - early breast cancer (ebc)phesgo is indicated for use in combination with chemotherapy in:the neoadjuvant treatment of adult patients with her2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrencethe adjuvant treatment of adult patients with her2-positive early breast cancer at high risk of recurrencemetastatic breast cancer (mbc)phesgo is indicated for use in combination with docetaxel in adult patients with her2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-her2 therapy or chemotherapy for their metastatic disease.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

roche registration gmbh - obinutuzumab - lewkimja, linfokitika, kronika, b-Ċellula - aġenti antineoplastiċi - lewkimja limfoċitika kronika (cll)gazyvaro flimkien ma 'chlorambucil huwa indikat għall-kura ta' pazjenti adulti li ma kienux ikkurati qabel lewkimja limfoċitika kronika (cll) u ma 'ko-morbożità li tagħmilhom tajbin għall-full-doża ta' fludarabine bbażata fuq it-terapija (ara sezzjoni 5. limfoma follikulari (fl)gazyvaro flimkien mal-kimoterapija, segwit minn gazyvaro terapija ta 'manteniment fil-pazjenti li laħqu rispons, huwa indikat għall-kura ta' pazjenti li ma kienux ikkurati qabel avvanzati limfoma follikulari. gazyvaro flimkien ma bendamustine segwit minn gazyvaro-manutenzjoni huwa indikat għall-kura ta ' pazjenti b'limfoma follikulari (fl) li ma jkunux irrispondew jew li żviluppaw waqt jew sa 6 xhur wara kura b'rituximab jew rituximab-reġimen li fih.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

abbvie deutschland gmbh co. kg - venetoclax - lewkimja, linfokitika, kronika, b-Ċellula - aġenti antineoplastiċi - venclyxto in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. venclyxto in combination with rituximab is indicated for the treatment of adult patients with cll who have received at least one prior therapy. venclyxto monotherapy is indicated for the treatment of cll:- in the presence of 17p deletion or tp53 mutation in adult patients who are unsuitable for or have failed a b cell receptor pathway inhibitor, or- in the absence of 17p deletion or tp53 mutation in adult patients who have failed both chemoimmunotherapy and a b-cell receptor pathway inhibitor. venclyxto in combination with a hypomethylating agent is indicated for the treatment of adult patients with newly  diagnosed acute myeloid leukaemia (aml) who are ineligible for intensive chemotherapy.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

astrazeneca ab - acalabrutinib - lewkimja, linfokitika, kronika, b-Ċellula - antineoplastic agents, protein kinase inhibitors, - calquence as monotherapy or in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll). calquence as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukaemia (cll) who have received at least one prior therapy.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

roche registration gmbh  - glofitamab - lymphoma, large b-cell, diffuse - aġenti antineoplastiċi - columvi as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large b cell lymphoma (dlbcl), after two or more lines of systemic therapy.